Isconova’s adjuvant technology is based on the Immune Stimulating Complex (ISCOM) technology platform. Different saponin combinations that form different matrix structures have been identified and isolated from the Quillaja Saponaria stock extract.

Isconova has utilized selected fractions to develop modern, multi-purpose, immune-modulating adjuvant products for a broad range of applications within vaccine development and immunology research.

With over 450 published articles and reviews, ISCOM technology is well-established and accepted. It also enjoys strong patent protection. Several licensing and manufacturing agreements have been signed, and a number of animal vaccines based on the technology are registered and marketed by major animal vaccine corporations.